文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

特发性肺纤维化合并肺动脉高压患者肺移植术后早期死亡的危险因素

[Risk factors of early death after lung transplantation in patients with idiopathic pulmonary fibrosis complicated with pulmonary arterial hypertension].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论特发性肺纤维化合并肺动脉高压患者肺移植术后180天生存率67.4%,术前使用激素、NT-proBNP≥300 ng/L、NYHA心功能III-IV级是早期死亡的独立危险因素。

该回顾性队列研究纳入2017年1月至2020年12月在南京医科大学附属无锡市人民医院接受肺移植的134例特发性肺纤维化(IPF)合并肺动脉高压(PAH)患者,收集供者、受者及手术因素,用Kaplan-Meier法计算术后30、60、180天累积生存率,用单因素和多因素Cox比例风险回归分析早期死亡危险因素。结果显示术后30、60、180天生存率分别为81.3%、76.9%、67.4%。多因素分析中,受者术前使用激素(模型1:HR=2.072,95%CI 1.044-4.114,P=0.037;模型2:HR=2.098,95%CI 1.057-4.165,P=0.034)、NT-proBNP≥300 ng/L(HR=2.246,95%CI 1.225-4.116,P=0.009)和NYHA心功能III-IV级(HR=2.771,95%CI 1.495-5.134,P=0.001)是术后早期死亡的独立危险因素。作者认为应重视术前功能状态优化,术前减少受者激素使用并改善心功能可提高此类患者肺移植术后早期生存率。

要点

  • 134例IPF合并PAH肺移植患者术后30、60、180天生存率分别为81.3%、76.9%、67.4%。
  • 多因素Cox分析:术前使用激素模型1 HR=2.072(95%CI 1.044-4.114,P=0.037)、模型2 HR=2.098(95%CI 1.057-4.165,P=0.034)。
  • 多因素Cox分析:NT-proBNP≥300 ng/L的HR=2.246(95%CI 1.225-4.116,P=0.009)。
  • 多因素Cox分析:NYHA心功能III-IV级的HR=2.771(95%CI 1.495-5.134,P=0.001)。
  • 单因素Cox分析:mPAP≥35 mmHg的HR=2.136(95%CI 1.129-4.044),为术后早期死亡危险因素(P<0.05)。

适用人群与场景

  • 2017年1月至2020年12月在南京医科大学附属无锡市人民医院接受肺移植的IPF合并PAH患者134例。
  • 受者以男性为主(83.6%),多数年龄<65岁(70.9%),多数无高血压(75.4%)或糖尿病(67.9%)。
  • 供者以男性为主(80.6%),63.4%的供者年龄>35岁,80.6%的供者机械通气时间<10天,中位冷缺血时间465.00(369.25,556.25)分钟。

诊断标准与关键阈值

  • 受者中位mPAP为36(30,43)mmHg(1 mmHg≈0.133 kPa)。
  • NT-proBNP阈值:≥300 ng/L。
  • 心功能分级:纽约心脏协会(NYHA)心功能III-IV级。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入134例IPF合并PAH肺移植患者;单肺移植73例(54.5%),双肺移植61例(45.5%)。
  • 术后30、60、180天累积生存率分别为81.3%、76.9%、67.4%。
  • 单因素Cox分析:受者术前使用激素HR=2.079(95%CI 1.048-4.128)、mPAP≥35 mmHg HR=2.136(95%CI 1.129-4.044)、NT-proBNP≥300 ng/L HR=2.411(95%CI 1.323-4.392)、NYHA心功能III-IV级HR=3.021(95%CI 1.652-5.523),均为术后早期死亡危险因素(均P<0.05)。
  • 多因素Cox分析:术前使用激素模型1 HR=2.072(95%CI 1.044-4.114,P=0.037)、模型2 HR=2.098(95%CI 1.057-4.165,P=0.034);NT-proBNP≥300 ng/L HR=2.246(95%CI 1.225-4.116,P=0.009);NYHA心功能III-IV级HR=2.771(95%CI 1.495-5.134,P=0.001),均为独立危险因素。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于IPF合并PAH的肺移植患者,应重视术前优化功能状态;术前减少受者激素使用并改善心功能可提高此类患者术后早期生存率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the risk factors of early death after lung transplantation in patients with idiopathic pulmonary fibrosis (IPF) complicated with pulmonary arterial hypertension (PAH).

METHODS: A retrospective cohort study was conducted. The clinical data of 134 patients with IPF and PAH who underwent lung transplantation at Wuxi People's Hospital Affiliated to Nanjing Medical University from January 2017 to December 2020 were collected. The donor's gender, age, duration of mechanical ventilation, and cold ischemia time, the recipient's gender, age, body mass index (BMI), smoking, history of hypertension and diabetes, preoperative usage of hormones, mean pulmonary arterial pressure (mPAP), cardiac echocardiography and cardiac function, serum creatinine (SCr), N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as surgical type, extracorporeal membrane oxygenation (ECMO) treatment, duration of operation, and plasma and red blood cell infusion ratio were collected. The cumulative survival rates of patients at 30, 60, and 180 days after lung transplantation were calculated by Kaplan-Meier method. The univariate and multivariate Cox proportional hazards regression models were used to analyze the effects of donor, recipient, and surgical factors on early survival in donors after lung transplantation.

RESULTS: The majority of donors were male (80.6%). There was 63.4% of the donors older than 35 years old, 80.6% of the donors had mechanical ventilation duration less than 10 days, and the median cold ischemia time was 465.00 (369.25, 556.25) minutes. The recipients were mainly males (83.6%). Most of the patients were younger than 65 years old (70.9%). Most of them had no hypertension (75.4%) or diabetes (67.9%). The median mPAP of recipients was 36 (30, 43) mmHg (1 mmHg ≈ 0.133 kPa). There were 73 patients with single lung transplantation (54.5%), and 61 with double lung transplantation (45.5%). The survival rates of 134 IPF patients with PAH at 30, 60, 180 days after lung transplantation were 81.3%, 76.9%, and 67.4%, respectively. Univariate Cox proportional risk regression analysis showed that recipient preoperative use of hormone [hazard ratio (HR) = 2.079, 95% confidence interval (95%CI) was 1.048-4.128], mPAP ≥ 35 mmHg (HR = 2.136, 95%CI was 1.129-4.044), NT-proBNP ≥ 300 ng/L (HR = 2.411, 95%CI was 1.323-4.392), New York Heart Association (NYHA) cardiac function classification III-IV (HR = 3.021, 95%CI was 1.652-5.523) were the risk factors of early postoperative death in patients with IPF complicated with PAH (all P < 0.05). In the multivariable Cox proportional risk regression analysis, recipient preoperative hormone usage (model 1: HR = 2.072, 95%CI was 1.044-4.114, P = 0.037; model 2: HR = 2.098, 95%CI was 1.057-4.165, P = 0.034), NT-proBNP ≥ 300 ng/L (HR = 2.246, 95%CI was 1.225-4.116, P = 0.009) and NYHA cardiac function classification III-IV (HR = 2.771, 95%CI was 1.495-5.134, P = 0.001) were independent risk factors of early postoperative death in patients with IPF.

CONCLUSIONS: Preoperative hormone usage, NT-proBNP ≥ 300 ng/L, NYHA cardiac function classification III-IV are independent risk factors for early death in patients with IPF and PAH after lung transplantation. For these patients, attention should be paid to optimize their functional status before operation. Preoperative reduction of receptor hormone usage and improvement of cardiac function can improve the early survival rate of such patients after lung transplantation.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Hu C, Liu M, Yu H, et al. [Risk factors of early death after lung transplantation in patients with idiopathic pulmonary fibrosis complicated with pulmonary arterial hypertension]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916370. doi:10.3760/cma.j.cn121430-20220523-00506

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。